Vitiligo - Bitiligo
☆ AI Dermatology — Free Service
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Non-segmental vitiligo (Segmenturik gabeko vitiligoa)
Behatzen vitiligoa beste eremu batzuk baino zailagoa da tratatzeko. Kosmetikoki itxuragabea izateaz gain, vitiligoa normala da eta ez da kutsakorra. Dermatologian, tratamendu eraginkorrena fototerapia edo laser tratamendua (excimer) da, astean 2‑3 aldiz gutxienez, urtebetez. Diru-arazoengatik edo lanpetuta zaudelako, ezin bazara askotan ospitalera joan, etxean erabiltzeko onartuta dagoen fototerapia-makina probatu dezakezu.
Vitiligoa esku artean.
relevance score : -100.0%
ReferencesVitiligo larruazaleko nahaste arrunta da, melanozitoen galeraren ondorioz azal zurian adabakiak eragiten dituen gaia. Azken ikerketek erakusten dute gaixotasun autoimmune bat dela. Askotan arazo kosmetiko gisa ikusten den arren, buruko ongizatean eta eguneroko bizitzan eragin handia izan dezake. 2011an, adituek segmental vitiligo izeneko mota besteetatik bereizita sailkatu zuten.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Bitiligo aktiboak dituzten pazienteek hainbat terapia aukera dituzte, hala nola glukokortikoide sistemikoak, fototerapia eta immunosupresore sistemikoak. Bitiligo kronikoak dituzten pazienteek kortikoide topikoen, kaltzineurinaren inhibitzaile topikoen, fototerapiaren eta transplantazio prozeduren erlieba aurki dezakete. Bitiligoaren azpiprozesuak ulertzeko azken aurrerapenek oinarritutako terapia berriak garatu dituzte. Gaur egun, JAK inhibitzaileak itxaropentsuenak dira, jasangarritasun ona eta emaitza funtzionalak eskaintzen dituztelako, nahiz eta infekzio ezkutuak eta beste agente immunosupresore batzuekin ohikoak diren bigarren mailako efektu sistemikoak aktibatzeko arriskua izan. Etengabeko ikerketek bitiligoaren garapenean parte hartzen duten zitokinak identifikatzea dute (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Zitokina hauek blokeatzea itxaropentsua izan da animalia-ereduetan eta paziente batzuetan. Gainera, miRNA‑based therapeutics eta adoptive Treg cell therapy ikerketak abian daude.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ez dago bitiligorako sendabide ezagunik. Azala argia dutenentzat, eguzkitako krema eta makillajea normalean gomendatzen dira. Beste tratamendu aukera batzuk esteroide kremak edo fototerapia izan daitezke.
○ Tratamendua
#Phototherapy
#Excimer laser
#Tacrolimus ointment